Jeannette Lee, Ph.D.

Research Professor; Senior Biostatistician

Education/Training:

Boston University, A.B. 1972, Mathematics
Johns Hopkins University, Ph.D. 1977, Biostatistics

Positions:

1976-1981 Instructor (1976-1979), Assistant Professor (1979-1981), Division of Radiation Oncology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO.

1981-1982 Assistant Professor, Division of Radiation Therapy, SUNY Upstate Medical Center, Syracuse, NY.

1983-1985 Research Biostatistician (1983-1984), Senior Biostatistician (1984-1985), Pharmaceutical Research and Development Division, Bristol-Myers Company, Syracuse, NY.

1986–1999 Research Associate Professor (1986-1999), Research Professor (1999-present), Medical Statistics Section (4/98), Division of Hematology/Oncology, Department of Medicine, University of Alabama School of Medicine, University of Alabama at Birmingham, Birmingham, AL.

1986-Present Senior Biostatistician, Biostatistics Unit, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL.

1999-Present Research Professor, Medical Statistics Section, Division of Hematology/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.

Honors:

NIH Traineeship (1972 - 1976)

Selected peer-reviewed publications (in chronological order):

  1. Lee JY, Breaux SR: Accrual of radiation therapy patients to clinical trials. Cancer 52:1014-1016, 1983.
  2. LoBuglio AF, Saleh M, Lee J, Khazaeli MB, Carrano R, Holden H and Wheeler R: Phase I Trial of Repetitive Large Doses of Murine Monoclonal Antibody 17-1A I. Clinical Aspects. Journal of the National Cancer Institute 80:932-936, 1988.
  3. Lee JY and Soong S-j: An overview of Alabama cancer mortality among whites: 1950-1980. Alabama Journal of Medical Sciences 25:375-382, 1988.
  4. Lee JY and Soong S-j: Cancer mortality in the South, 1950 to 1980. Southern Medical Journal 83:185-190, 1990.
  5. Saleh MN, LoBuglio AF, Wheeler RH, Rogers KJ, Haynes A, Lee JY and Khazaeli MB: A Phase II trial of murine monoclonal antibody 17-1A and 8-IFN-Clinical and Immunologic data. Cancer Immunology and Immunotherapy 32:185-190, 1990.
  6. Dismukes WE, Wade JS, Lee JY, Dockery BK and Hain JD: Nystatin therapy of candidiasis hypersensitivity syndrome: results of a prospective, randomized clinical trial. New England Journal of Medicine 323(25):1717-1723, 1990.
  7. Lee JY, Oberman A, Fletcher GF, Raczynski JM, Fletcher BJ, Nanda NC and Jensen BE: Design of the Training Levels Comparison Trial. Controlled Clinical Trials 15(1):59-76, 1994.
  8. Lee JY: Uses of Clinical Databases. American Journal of Medical Sciences 308(1):58-62, 1994.
  9. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A, Gallis H, Perfect JR, Dockery B, Dismukes WE, Stevens DA: NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy of invasive aspergillosis. American Journal of Medicine 97:135-144, 1994.
  10. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL and Alarcon GS: Supplementation with folic acid during methotrexate therapy of rheumatoid arthritis: results from a double-blind, placebo-controlled trial. Annals of Internal Medicine 121(11):833-841, 1994.
  11. Lee JY, Jensen BE, Oberman A, Fletcher GF, Fletcher BJ and Raczynski JM: Adherence in the Training Levels Comparison Trial. Medicine and Science in Sports and Exercise 28(1):47-52, 1996.
  12. Lee JY, Greene PG, Douglas M, Grim C, Kirk KA, Milligan S, Smith DE and Whelton PK: Appointment attendance, pill counts and achievement of target blood pressure in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials 17:17S-33S, 1996.
  13. Lee J, Bernhard S, Douglas M, Greene P, Kusek J, Norris K and Whelton P: Assessing medication adherence in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. American Journal of Hypertension 9:719-725, 1996.
  14. Whelton PK, Lee JY, Kusek JW, Charleston J, DeBruge J, Douglas M, Faulkner M, Greene P, Jones C, Kiefer S, Kirk KA, Levell B, Norris K, Powers S, Retta TM, Smith DE, and Ward H: Recruitment in the African American Study of Kidney Disease and Hypertension. Controlled Clinical Trials 17:34S-39S, 1996.
  15. Kusek JW, Lee JY, Smith DE, Milligan S, Faulkner M, Cornell CM, Kopple J and Greene PG: Effect of blood pressure control and antihypertensive drug regimen on quality of life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Controlled Clinical Trials 17:40S-46S, 1996.
  16. Knoll GA, Tankersley MR, Lee JY, Julian BA and Curtis JJ: The impact of renal transplantation on survival in Hepatitis C positive end-stage renal disease patients. American Journal of Kidney Diseases. 29(4):608-14, 1997.
  17. Stevens DA and Lee JY: Analysis of compassionate use itraconazole therapy of invasive aspergillosis by the NIAID Mycoses Study Group. Archives of Internal Medicine, 157: 1857-1862, 1997.
  18. Julian BA, Brantley RR Jr, Barker CV, Stopka T, Gaston RS, Curtis JJ, Lee JY and Prchal JT: Losartan, an angiotensin II type I receptor antagonist, lowers hematocrits in posttransplant erythrocytosis. Journal of the American Society of Nephrology 9:1104-1108, 1998.
  19. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS, Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Medicine 4(11):1302-7, 1998.
  20. O'Sullivan CE, Drew WL, McMullen DJ, Miner R, Lee JY, Kaslow RA, Lazar JG, Saag MS. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. Journal of Infectious Diseases. 180 (3):847-9, 1999
  21. Saag MS, Fessel WJ, Kaufman C, Merrill KW, Ward DJ, Moskovitz BL, Thomas C, Oleka N, Guarnieri JA, Lee J, Brenner-Gati L, Klausner M. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients. AIDS Research and Human Retroviruses 15 (16): 1413-1417, 1999.
  22. Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, Bamberger DM, Weinmann AJ, Tuazon CU, Judson MA, Platts-Mill TAE and DeGraff AC, Jr.: A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. New England Journal of Medicine 342:756-62, 2000.
  23. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan L, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B and Straus D for the AIDS Malignancy Consortium. Chemotherapy for HIV-associated non-Hodgkin’s Lymphoma in Combination with Highly Active Antiretroviral Therapy. Journal of Clinical Oncology 19(8):2165-2170, 2001.
  24. Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Ratner L, Pluda JM, Figg WD, Krown SE and Dezube BJ. Angiogenesis inhibitor COL-3 in the treatment of AIDS-related Kaposi’s sarcoma: a phase I AIDS Malignancy Consortium Study. Journal of Clinical Oncology 20:153-159,2002.
  25. Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW, Morrison VA, Pappas P, Hiemenz JW and Stevens DA and the NIAID-sponsored Mycoses Study Group. The impact of culture isolation of aspergillus: a hospital-based survey of aspergillosis. Clinical Infectious Diseases 33:1824-33, 2001.
  26. Walsh TJ, Pappas PG, Winston D, Lazarus HM, Petersen F, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, and Lee J for the NIAID Mycoses Study Group. Voriconazole versus liposomal amphotericin B for the empirical antifungal therapy in persistently febrile neutropenic patients: a prospective, randomized, multicenter, international trial. New England Journal of Medicine 346(4):225-234, 2002.
  27. van Burik JH, Ratanatharathorn V, Stepan DE, Miller CB, Lipton J, Vesole DH, Bunin N, Wall D, Satoi, Lee J, and Walsh TJ. Micafungin versus Fluconazole for prophylaxis of invasive fungal infections during neutropenia in patient undergoing hematopoietic stem cell transplantation. Clinical Infectious Diseases, 2004. (In press)

Research Support:

ONGOING

CA-13148 LoBuglio (PI) 04/01/2005 - 03/31/2010
NIH/NCI
Cancer Center Core Support Grant

This grant supports the leadership, clinical and basic science program leaders, developmental programs, and shared resources for the Comprehensive Cancer Center at the University of Alabama at Birmingham.

5U01 CA70019 Lee (PI) 08/01/1999 - 07/31/2006
NIH/NCI
Operations Center for AIDS-Associated Malignancies

The Biostatistics Unit of the UAB Comprehensive Cancer Center serves as the operations, statistical and data management center for the AIDS-associated malignancies clinical trials consortium. The center provides operational, statistical and data management support for 4 to 6 phase I and II clinical trials annually which are carried out in 15 clinical centers and their affiliates.

P30 AI27767 Hunter (PI) 03/01/2003 - 02/28/2008
NIH
Birmingham Center for AIDS Research

The Biostatistics Core Facility serves as the centralized resource for statistical expertise and data management services to support the research programs and projects conducted by the members of the Birmingham Center for AIDS Research.

RFA CA-01-13 Fouad (PI) 09/01/2001-08/31/06
Deep South CanCORS Colorectal and Lung Cancer PDCR Site

UAB serves as a Primary Data Collection and Research (PDCR) site in the Cancer Care Outcomes Research and Surveillance Consortium. The site plans to enroll 700 lung cancer and 700 colorectal cancer patients in the Consortium Areas of focus for consortium activities are 1) variations in processes and outcomes of care among vulnerable populations defined by age, socioeconomic status, and race, and 2) the role of modifiable lifestyle factors on outcomes.

1K30 HL04146 Moreland (PI) 07/01/1999 - 06/30/2004
NHLBI/NIH
UAB Clinical Research Training Program

The Clinical Research Training Program (CRTP) is a formal program designed to provide trainee clinical investigators with the skills and conceptual framework necessary for the conduct of clinical research.

1 P01 DK61525 Mestecky (PI) 06/15/2002 - 03/31/2007
NIDDK/NIH
Familial IgA Nephropathy: Genetic and Metabolic Studies

The objective of this program project is to determine the molecular and genetic basis of IgA nephropathy, the regulatory mechanisms for the product of aberrantly glycosylated IgA1 molecules and IgA1-containing immune complexes.

U01 DK 603788-01 Lee (PI) 10/01/2002 - 09/30/2009
NIH/NIDDK
Complementary and Alternative Medicine for Urological Symptoms (CAMUS)

This proposal is for UAB to serve as the Data Coordinating Center for a multicenter trial of alternative therapies (phytotherapies) in the treatment of benign prostate symptoms. It is anticipated that 10 clinical centers will enroll approximately 3100 men with benign prostatic hyperplasia on this study.